Browsing by Author "Çetinkalp Ş."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Trigliserit nedir? Normal fizyolojideki yeri nedir?
    (Turkish Society of Cardiology, 2017) Çetinkalp Ş.; Koylan N.; Özer N.; Onat A.; Gökhan Özgen A.; Lale Koldaş Z.; Güven G.S.; Özdoğan Ö.; Karşıdağ K.; Yiğit Z.; Kayıkçıoğlu M.; Tokgözoğlu L.; Can L.H.; Tartan Z.; Kültürsay H.; Karpuz B.; Kırılmaz B.; Ersanlı M.; Ural D.; Erbakan A.N.; Oğuz A.; Kayıkçıoğlu Ö.R.; Temizhan A.; Sansoy V.; Ceyhan C.; Öngen Z.; Bayram F.; Örem C.; Sönmez A.; Beyaz Ş.; Ükinç K.; Yürekli B.Ş.; Çoker M.; Canda E.; Şimşir I.Y.
    [No abstract available]
  • No Thumbnail Available
    Item
    Analysis of the GCK gene in 79 MODY type 2 patients: A multicenter Turkish study, mutation profile and description of twenty novel mutations
    (Elsevier B.V., 2018) Aykut A.; Karaca E.; Onay H.; Gökşen D.; Çetinkalp Ş.; Eren E.; Ersoy B.; Çakır E.P.; Büyükinan M.; Kara C.; Anık A.; Kırel B.; Özen S.; Atik T.; Darcan Ş.; Özkınay F.
    Maturity onset diabetes is a genetic form of diabetes mellitus characterized by an early age at onset and several etiologic genes for this form of diabetes have been identified in many patients. Maturity onset diabetes type 2 [MODY2 (#125851)] caused by mutations in the glucokinase gene (GCK). Although its prevalence is not clear, it is estimated that 1%–2% of patients with diabetes have the monogenic form. The aim of this study was to evaluate the molecular spectrum of GCK gene mutations in 177 Turkish MODY type 2 patients. Mutations in the GCK gene were identified in 79 out of 177. All mutant alleles were identified, including 45 different GCK mutations, 20 of which were novel. © 2017
  • No Thumbnail Available
    Item
    Prevalence of Vitamin D Deficiency and Hypervitaminosis D Among Adult Patients Admitted to the Tertiary Care Hospitals in Turkey
    (Turkiye Klinikleri, 2022) Yavuz D.G.; Ersoy R.; Altuntaş Y.; Bilen H.; Pamuk B.; Apaydın T.; Temizkan Ş.; Altuntaş H.; Mert M.; Akalın A.; Sert M.; Şimşir I.Y.; Hekimsoy Z.; Cantürk Z.; Üç Z.A.; İplikçi S.; Yaşar M.; Unubol M.; Sezer K.; Toplaoğlu Ö.; İyidir Ö.T.; Pekkolay Z.; Atmaca A.; Dikbaş O.; Özdemir N.; Gül K.; Deniz F.; Ertörer E.; Karaca Z.; Elbüken G.; Arpacı D.; Ağbaht K.; Turan E.; Anaforoğlu İ.; Bayraktaroğlu T.; Haklar G.; Dağlıoğlu G.; Tuzcu A.; Şahin İ.; Çetinkalp Ş.
    Objective: Vitamin D deficiency is a common health problem around the world. This study aimed to evaluate the nationwide prevalence of vitamin D status in tertiary care hospitals in Turkey. Methods: Retrospectively, the data on vitamin D levels from 33 tertiary care hospitals’ clinical biochemistry laboratories around Turkey between January and December were collected. Results: In total, 706 434 serum samples from adult subjects (female/male: 469 028/237 406; 66.4%/33.6%) were included. While vitamin D levels were sufficient in 20.3% (n = 14 222), they were insufficient in 21.9% (n = 154 360) and deficient in 57.8% (n = 408 882). We observed the highest rates of deficiency in those aged between 18 and 29 years (62.9%, n = 70 235) and lowest rates between 60 and 69 years (52.3%, n = 61 121) and between 70 and 79 years (52.3%, n = 32 397). Hypervitaminosis D was detected in 5.5% of adult subjects; highest rates of hypervitaminosis D were observed in those who were over 80 years (6.6%) and 70-79 years (6.5%) and the lowest in 18-29 years (2.8%). Discussion: In this cohort, over half of the subjects admitted to the tertiary care hospitals in Turkey had vitamin D deficiency and required vitamin D supplementation. The elderly population had the lowest prevalence of vitamin D insufficiency and the highest prevalence of hypervitaminosis D. © Author(s).
  • No Thumbnail Available
    Item
    Effectiveness and Safety of Initiation and Titration of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetic Drug Treatment in Turkey: The EASE Study
    (AVES, 2024) Çetinarslan B.; Çetinkalp Ş.; Kaya A.; Ersoy C.; Kebapçı N.; Çömlekçi A.; Tütüncü N.B.; Deyneli O.; Oğuz A.; İlkova H.; Yılmaz T.; Hekimsoy Z.; Ünübol M.; Balcı M.K.; Atmaca A.; Dağdelen S.; Yetkin İ.; Güler S.; Ötünç G.; Özhan L.
    Objective: The aim of the study was to evaluate the effectiveness and safety of insulin glargine 300 U/ mL (Gla-300) in insulin-naive patients with type 2 diabetes mellitus (T2DM) inadequately controlled on oral antidiabetic drug (OADs) treatment in Turkey. Methods: One hundred eight patients from 20 centers enrolled in the study. Starting from baseline, Gla-300 was self-administered subcutaneously and once daily in the evening. The primary outcome was the mean change in glycated hemoglobin A1c (HbA1c) from baseline to week 24. Results: The mean (±SD) Hb1Ac level of 9.4% (±0.8) at baseline decreased to 7.5% (±0.9) at week 12 (P <.1) and to 7.3% (±0.9) at week 24 (P <.1). Although none of the patients were within the target Hb1Ac level of ≤7% at baseline, the percentage of patients who achieved the target Hb1Ac level was 30.4% at week 12 and increased to 42.9% at week 24. Gla-300 treatment achieved the Hb1Ac target in 21 (19.4%) patients without experiencing a hypoglycemic event and in 27 (25.0%) patients who experienced at least one hypoglycemic event. For each self-monitoring blood glucose time point, significant improvements were observed as compared to baseline (P <.001). Statistically significant improvement (P <.001) was seen in the treatment satisfaction questionnaire – status version scores between baseline and week 24. Conclusion: This study indicated that Gla-300 is effective to provide a successful glycemic control with low risk of hypoglycemia added to OADs in insulin-naive patients with T2DM, and it has the potential to improve the quality of life of patients. © Author(s).